Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer.
Rahul R AggarwalJoshi J AlumkalRussell Z SzmulewitzCelestia S HiganoAlan H BryceAngela Lopez-GitlitzSharon A McCarthyBranko MiladinovicKelly McQuarrieShibu ThomasKe ZhangEric J SmallPublished in: Prostate cancer (2022)
HRQoL was similar in patients treated with apalutamide alone, ADT alone, or their combination, although apalutamide plus ADT did not demonstrate statistically significant noninferiority in change from baseline in overall HRQoL. The aggregated efficacy and safety outcomes support further evaluation of apalutamide plus ADT in BCR PC.
Keyphrases
- open label
- prostate cancer
- phase iii
- phase ii
- clinical trial
- phase ii study
- study protocol
- double blind
- acute lymphoblastic leukemia
- combination therapy
- placebo controlled
- randomized controlled trial
- adipose tissue
- radiation therapy
- stem cells
- insulin resistance
- squamous cell carcinoma
- mesenchymal stem cells
- rectal cancer
- locally advanced
- replacement therapy